Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment.

Elliott Vichinsky, MD, Amal El-Beshlawy, MD, Azzam Alzoebie, MD, Francoise Bernaudin, MD, Suzanne Koussa, MD, Thirachit Chotsampancharoen, MD, Ali El-Ali, MD, Caroline Arrowsmith, Nicolas Martin, MS, Mohsen El-Alfy, MD

Blood (2012) 120 (21): 2125.

https://doi.org/10.1182/blood.V120.21.2125.2125

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

NARROW

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment.

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only